NCT01751165已完成3 期
Open-label Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 354
- 试验地点
- 5
- 主要终点
- Concentrations of Antibodies Against Anti-gE as Determined by ELISA.
研究概览
简要总结
The purpose of this study is to assess the safety and immunogenicity of the GSK Biologicals' HZ vaccine 1437173A administered on either a 0,2-; 0,6- or 0,12-month schedule in adults aged 50 years or above, as the immunogenicity of the HZ vaccine administered at intervals longer than two months is not known.
详细描述
Subjects in each group will be stratified by age with a minimum of 35 subjects in each stratum (50-59 years of age (YOA) stratum, 60-69 YOA stratum and ≥ 70 YOA stratum).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •A male or female aged 50 years or older at the time of the first vaccination.
- •Written informed consent obtained from the subject.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
- •Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •has practiced adequate contraception for 30 days prior to vaccination, and
- •has a negative pregnancy test on the day of vaccination, and
- •has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series.
排除标准
- •Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, a prednisone dose of < 20 mg/day, or equivalent, is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
- •Administration or planned administration of a live vaccine in the period starting 30 days before and ending 30 days after either dose of study vaccine.
- •Administration or planned administration of a non-replicating vaccine within eight days prior to or within 14 days after either dose of study vaccine.
- •Administration of long-acting immune-modifying drugs (e.g. infliximab) within six months prior to the first vaccine dose or expected administration at any time during the study period.
- •Previous vaccination against varicella or HZ (either registered product or participation in a previous vaccine study).
- •Planned administration during the study of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
- •History of HZ.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).
- •Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g. malignancy, human immunodeficiency virus [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g. medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders).
- •Acute disease and/or fever at the time of enrolment.
- •Fever is defined as temperature ≥ 37.5°C (99.5°F) for oral, axillary or tympanic route, or ≥ 38.0°C (100.4°F) for rectal route. The preferred route for recording temperature in this study will be oral.
- •Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- •Significant underlying illness that, in the opinion of the investigator, would be expected to prevent completion of the study.
- •Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
- •Pregnant or lactating female.
- •Female planning to become pregnant during the entire treatment period and for two months after completion of the vaccination series, or planning to discontinue contraceptive precautions (if of childbearing potential).
研究组 & 干预措施
HZ/su-0,2 Group
Experimental
Subjects will receive HZ/su vaccine on a 0,2-month schedule.
干预措施: Herpes zoster vaccine GSK1437173A (Biological)
HZ/su-0,6 Group
Experimental
Subjects will receive HZ/su vaccine on a 0,6-month schedule.
干预措施: Herpes zoster vaccine GSK1437173A (Biological)
HZ/su-0,12 Group
Experimental
Subjects will receive HZ/su vaccine on a 0,12-month schedule.
干预措施: Herpes zoster vaccine GSK1437173A (Biological)
结局指标
主要结局
Concentrations of Antibodies Against Anti-gE as Determined by ELISA.
时间窗: At one month (M1) after Dose 2
Number of Subjects With Vaccine Response to Anti-glycoprotein E (Anti-gE) Antibodies as Determined by the Enzyme-linked Immunosorbent Assay (ELISA).
时间窗: At one month (M1) after Dose 2
Vaccine response was defined as: for initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. The objective required a comparison of VRR between 0,6-months and 0,12-months schedules.
次要结局
- Number of Subjects With Solicited General Symptoms.(During the 7 day period (Days 0-6) following each dose (D))
- Number of Subjects With SAE(s).(Starting from 30 Days post last vaccine administration up to study end at Month 24)
- Number of Subjects With Unsolicited Adverse Events (AEs).(During the 30 Days (Day 0-29) following vaccination)
- Number of Days With Solicited General Symptoms.(During the 7 Days (Day 0-6) following vaccination)
- Concentrations of Antibodies Against Anti-gE as Determined by ELISA.(Prior (PRE) to vaccination and twelve (M12) post Dose 2)
- Number of Subjects With Solicited Local Symptoms.(During the 7 day period (Days 0-6) following each dose (D))
- Number of Subjects With Serious Adverse Events (SAEs).(From first vaccination up to one month (30 Days) post last vaccination)
- Number of Subjects With Potential Immune-mediated Diseases (pIMDs).(From Dose 1 up to one month (30 days) following the last vaccine dose administration (Dose 2))
- Number of Days With Solicited Local Symptoms.(During the 7 Days (Day 0-6) following vaccination)
- Number of Subjects With pIMDs.(From one month (30 Days) following the last vaccine administration up to study end at Month 24)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes ZosterHerpes ZosterNCT04091451GlaxoSmithKline1,430
已完成
3 期
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years EarlierHerpes ZosterNCT02581410GlaxoSmithKline430
已完成
3 期
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal TransplantHerpes ZosterNCT02058589GlaxoSmithKline265
已完成
3 期
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes ZosterHerpes ZosterNCT01827839GlaxoSmithKline96
已完成
3 期
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving ChemotherapyHerpes Zoster VaccineHerpes ZosterNCT01798056GlaxoSmithKline237